| D008297 |
Male |
|
Males |
|
| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D005260 |
Female |
|
Females |
|
| D006111 |
Graves Disease |
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). |
Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D013967 |
Thyroiditis, Autoimmune |
Inflammatory disease of the THYROID GLAND due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-CELLS and thyroid AUTOANTIBODIES. The clinical signs can range from HYPOTHYROIDISM to THYROTOXICOSIS depending on the type of autoimmune thyroiditis. |
Autoimmune Thyroiditis,Thyroiditis, Lymphocytic,Thyroiditis, Lymphomatous,Autoimmune Thyroiditides,Lymphocytic Thyroiditides,Lymphocytic Thyroiditis,Lymphomatous Thyroiditides,Lymphomatous Thyroiditis,Thyroiditides, Autoimmune,Thyroiditides, Lymphocytic,Thyroiditides, Lymphomatous |
|
| D015536 |
Down-Regulation |
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. |
Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor |
|
| D015854 |
Up-Regulation |
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. |
Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation |
|
| D050031 |
Hashimoto Disease |
Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM. |
Hashimoto's Disease,Chronic Lymphocytic Thyroiditis,Hashimoto Struma,Hashimoto Thyroiditis,Hashimoto's Struma,Hashimoto's Syndrome,Chronic Lymphocytic Thyroiditides,Disease, Hashimoto,Disease, Hashimoto's,Hashimoto Syndrome,Hashimoto Thyroiditides,Hashimoto's Syndromes,Hashimotos Disease,Hashimotos Syndrome,Lymphocytic Thyroiditides, Chronic,Lymphocytic Thyroiditis, Chronic,Syndrome, Hashimoto's,Syndromes, Hashimoto's,Thyroiditides, Chronic Lymphocytic,Thyroiditides, Hashimoto,Thyroiditis, Chronic Lymphocytic,Thyroiditis, Hashimoto |
|
| D053264 |
B-Cell Activating Factor |
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN. |
Antigens, CD257,BAFF Ligand,CD257 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 13b,B Cell Activating Factor,B Lymphocyte Stimulator,B-Lymphocyte Activating Factor,BLyS Protein,CD257 Antigen,TALL-1 Protein,THANK Protein,TNF Superfamily, Member 13b,TNF and APOL-Related Leukocyte Expressed Ligand 1,TNFSF13B Protein,Activating Factor, B-Cell,Activating Factor, B-Lymphocyte,Antigen, CD257,B Lymphocyte Activating Factor,TALL 1 Protein,TNF and APOL Related Leukocyte Expressed Ligand 1 |
|
-transparent.png){kind=logo}
